Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 416 entries
Sorted by: Best Match Show Resources per page
Flow-injection spectrophotometric determination of reverse transcriptase inhibitors used for acquired immuno deficiency syndrome (AIDS) treatment: focus on strategies for dealing with the background components.

Analytica chimica acta

Checa A, Oliver R, Saurina J, Hernández-Cassou S.
PMID: 17723473
Anal Chim Acta. 2006 Jul 14;572(1):155-64. doi: 10.1016/j.aca.2006.05.041. Epub 2006 May 20.

This paper describes a rapid method for the quantification of reverse transcriptase inhibitors in mixtures of therapeutic interest containing zidovudine, zalcitabine and nevirapine. The method is based on a pH-gradient flow-injection system with diode array detection and further data...

Cite
Checa A, Oliver R, Saurina J, et al. Flow-injection spectrophotometric determination of reverse transcriptase inhibitors used for acquired immuno deficiency syndrome (AIDS) treatment: focus on strategies for dealing with the background components. Anal Chim Acta. 2006;572(1):155-64doi: 10.1016/j.aca.2006.05.041.
Checa, A., Oliver, R., Saurina, J., & Hernández-Cassou, S. (2006). Flow-injection spectrophotometric determination of reverse transcriptase inhibitors used for acquired immuno deficiency syndrome (AIDS) treatment: focus on strategies for dealing with the background components. Analytica chimica acta, 572(1), 155-64. https://doi.org/10.1016/j.aca.2006.05.041
Checa, Antonio, et al. "Flow-injection spectrophotometric determination of reverse transcriptase inhibitors used for acquired immuno deficiency syndrome (AIDS) treatment: focus on strategies for dealing with the background components." Analytica chimica acta vol. 572,1 (2006): 155-64. doi: https://doi.org/10.1016/j.aca.2006.05.041
Checa A, Oliver R, Saurina J, Hernández-Cassou S. Flow-injection spectrophotometric determination of reverse transcriptase inhibitors used for acquired immuno deficiency syndrome (AIDS) treatment: focus on strategies for dealing with the background components. Anal Chim Acta. 2006 Jul 14;572(1):155-64. doi: 10.1016/j.aca.2006.05.041. Epub 2006 May 20. PMID: 17723473.
Copy Download .nbib Format: NLM
Antiretroviral therapy: when to start and which drugs to use.

Current infectious disease reports

Anderson AM, Lennox JL.
PMID: 18765108
Curr Infect Dis Rep. 2008 Jul;10(4):332-9. doi: 10.1007/s11908-008-0053-4.

US guidelines for treating HIV infection now advocate antiretroviral therapy (ART) for all HIV-infected patients who have CD4(+) T-cell counts less than 350 cells/muL. Treatment is recommended for all pregnant women and patients with AIDS-defining illnesses. At least one...

Cite
Anderson AM, Lennox JL. Antiretroviral therapy: when to start and which drugs to use. Curr Infect Dis Rep. 2008;10(4):332-9doi: 10.1007/s11908-008-0053-4.
Anderson, A. M., & Lennox, J. L. (2008). Antiretroviral therapy: when to start and which drugs to use. Current infectious disease reports, 10(4), 332-9. https://doi.org/10.1007/s11908-008-0053-4
Anderson, Albert M, and Lennox, Jeffrey L. "Antiretroviral therapy: when to start and which drugs to use." Current infectious disease reports vol. 10,4 (2008): 332-9. doi: https://doi.org/10.1007/s11908-008-0053-4
Anderson AM, Lennox JL. Antiretroviral therapy: when to start and which drugs to use. Curr Infect Dis Rep. 2008 Jul;10(4):332-9. doi: 10.1007/s11908-008-0053-4. PMID: 18765108.
Copy Download .nbib Format: NLM
Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models.

Diabetology & metabolic syndrome

Mastan S, Kumar KE.
PMID: 19825151
Diabetol Metab Syndr. 2009 Oct 09;1(1):15. doi: 10.1186/1758-5996-1-15.

BACKGROUND: Type 2 diabetes may occur as a result of HIV infection and/or its treatment. Gliclazide is a widely used drug for the treatment of type 2 diabetes. Efavirenz and nevirapine are widely used non-nucleoside reverse transcriptase inhibitors for...

Cite
Mastan S, Kumar KE. Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models. Diabetol Metab Syndr. 2009;1(1):15doi: 10.1186/1758-5996-1-15.
Mastan, S., & Kumar, K. E. (2009). Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models. Diabetology & metabolic syndrome, 1(1), 15. https://doi.org/10.1186/1758-5996-1-15
Mastan, Sk, and Kumar, K Eswar. "Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models." Diabetology & metabolic syndrome vol. 1,1 (2009): 15. doi: https://doi.org/10.1186/1758-5996-1-15
Mastan S, Kumar KE. Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models. Diabetol Metab Syndr. 2009 Oct 09;1(1):15. doi: 10.1186/1758-5996-1-15. PMID: 19825151; PMCID: PMC2765430.
Copy Download .nbib Format: NLM
Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens.

Journal of the International AIDS Society

Doualla-Bell F, Gaolathe T, Avalos A, Cloutier S, Ndwapi N, Holcroft C, Moffat H, Dickinson D, Essex M, Wainberg MA, Mine M.
PMID: 19852859
J Int AIDS Soc. 2009 Oct 25;12:25. doi: 10.1186/1758-2652-12-25.

OBJECTIVE: Our objective was to establish genotypic resistance profiles among the 4% of Batswana patients who experienced virologic failure while being followed within Botswana's National Antiretroviral Treatment Program between 2002 and 2007.METHODS: At the beginning of the national program...

Cite
Doualla-Bell F, Gaolathe T, Avalos A, et al. Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens. J Int AIDS Soc. 2009;12:25doi: 10.1186/1758-2652-12-25.
Doualla-Bell, F., Gaolathe, T., Avalos, A., Cloutier, S., Ndwapi, N., Holcroft, C., Moffat, H., Dickinson, D., Essex, M., Wainberg, M. A., & Mine, M. (2009). Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens. Journal of the International AIDS Society, 1225. https://doi.org/10.1186/1758-2652-12-25
Doualla-Bell, Florence, et al. "Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens." Journal of the International AIDS Society vol. 12 (2009): 25. doi: https://doi.org/10.1186/1758-2652-12-25
Doualla-Bell F, Gaolathe T, Avalos A, Cloutier S, Ndwapi N, Holcroft C, Moffat H, Dickinson D, Essex M, Wainberg MA, Mine M. Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens. J Int AIDS Soc. 2009 Oct 25;12:25. doi: 10.1186/1758-2652-12-25. PMID: 19852859; PMCID: PMC2770537.
Copy Download .nbib Format: NLM
Nelfinavir and non-nucleoside reverse transcriptase inhibitor-based salvage regimens in heavily HIV pretreated patients.

The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses

Baril JG, Lefebvre EA, Lalonde RG, Shafran SD, Conway B.
PMID: 18159457
Can J Infect Dis. 2003 Jul;14(4):201-5. doi: 10.1155/2003/309724.

OBJECTIVE: To assess the efficacy of nelfinavir mesylate (NFV) in combination with delavirdine mesylate (DLV) or efavirenz (EFV) and other antiretroviral agents following virological failure on other protease inhibitor (PI)-based regimens.DESIGN: Multicentre, retrospective chart review.METHODS: One hundred-one patients who...

Cite
Baril JG, Lefebvre EA, Lalonde RG, et al. Nelfinavir and non-nucleoside reverse transcriptase inhibitor-based salvage regimens in heavily HIV pretreated patients. Can J Infect Dis. 2003;14(4):201-5doi: 10.1155/2003/309724.
Baril, J. G., Lefebvre, E. A., Lalonde, R. G., Shafran, S. D., & Conway, B. (2003). Nelfinavir and non-nucleoside reverse transcriptase inhibitor-based salvage regimens in heavily HIV pretreated patients. The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses, 14(4), 201-5. https://doi.org/10.1155/2003/309724
Baril, Jean-Guy, et al. "Nelfinavir and non-nucleoside reverse transcriptase inhibitor-based salvage regimens in heavily HIV pretreated patients." The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses vol. 14,4 (2003): 201-5. doi: https://doi.org/10.1155/2003/309724
Baril JG, Lefebvre EA, Lalonde RG, Shafran SD, Conway B. Nelfinavir and non-nucleoside reverse transcriptase inhibitor-based salvage regimens in heavily HIV pretreated patients. Can J Infect Dis. 2003 Jul;14(4):201-5. doi: 10.1155/2003/309724. PMID: 18159457; PMCID: PMC2094943.
Copy Download .nbib Format: NLM
Current therapy of HIV.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Potthoff AV, Brockmeyer NH.
PMID: 20096060
J Dtsch Dermatol Ges. 2010 Jan;8(1):45-56; quiz 57-8. doi: 10.1111/j.1610-0387.2009.07098_supp.x.

Antiretroviral therapy has improved continuously. Almost every year a new drug has been approved. Nucleoside analogs still build the backbone of antiretroviral therapy. They inhibit reverse transcriptase and thus the transcription of RNA to DNA. They are combined with...

Cite
Potthoff AV, Brockmeyer NH. Current therapy of HIV. J Dtsch Dermatol Ges. 2010;8(1):45-56; quiz 57-8doi: 10.1111/j.1610-0387.2009.07098_supp.x.
Potthoff, A. V., & Brockmeyer, N. H. (2010). Current therapy of HIV. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 8(1), 45-56; quiz 57-8. https://doi.org/10.1111/j.1610-0387.2009.07098_supp.x
Potthoff, Anja Verena, and Brockmeyer, Norbert H. "Current therapy of HIV." Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG vol. 8,1 (2010): 45-56; quiz 57-8. doi: https://doi.org/10.1111/j.1610-0387.2009.07098_supp.x
Potthoff AV, Brockmeyer NH. Current therapy of HIV. J Dtsch Dermatol Ges. 2010 Jan;8(1):45-56; quiz 57-8. doi: 10.1111/j.1610-0387.2009.07098_supp.x. German. PMID: 20096060.
Copy Download .nbib Format: NLM
6-Cyclo-hexyl-methyl-2-cyclo-hexyl-sul-fanyl-5-isopropyl-pyrimidin-4(3H)-one.

Acta crystallographica. Section E, Structure reports online

Zhang CS, Li DX, Zhang DH, He YP, Li C.
PMID: 21201750
Acta Crystallogr Sect E Struct Rep Online. 2008 Aug 16;64:o1768. doi: 10.1107/S1600536808025592.

The title compound, C(20)H(32)N(2)OS, was obtained during the course of our investigation on 2-alkylsulfanyl-6-benzyl-3,4-dihydropyrimidin-4(3H)-ones (S-DABOs) showing favourable anti-HIV-1 activity. Both cyclo-hexane rings adopt chair conformations. The angle at the methyl-ene C atom linking the pyrimidine and cyclo-hexane ring is...

Cite
Zhang CS, Li DX, Zhang DH, et al. 6-Cyclo-hexyl-methyl-2-cyclo-hexyl-sul-fanyl-5-isopropyl-pyrimidin-4(3H)-one. Acta Crystallogr Sect E Struct Rep Online. 2008;64:o1768doi: 10.1107/S1600536808025592.
Zhang, C. S., Li, D. X., Zhang, D. H., He, Y. P., & Li, C. (2008). 6-Cyclo-hexyl-methyl-2-cyclo-hexyl-sul-fanyl-5-isopropyl-pyrimidin-4(3H)-one. Acta crystallographica. Section E, Structure reports online, 64o1768. https://doi.org/10.1107/S1600536808025592
Zhang, Chun-Sheng, et al. "6-Cyclo-hexyl-methyl-2-cyclo-hexyl-sul-fanyl-5-isopropyl-pyrimidin-4(3H)-one." Acta crystallographica. Section E, Structure reports online vol. 64 (2008): o1768. doi: https://doi.org/10.1107/S1600536808025592
Zhang CS, Li DX, Zhang DH, He YP, Li C. 6-Cyclo-hexyl-methyl-2-cyclo-hexyl-sul-fanyl-5-isopropyl-pyrimidin-4(3H)-one. Acta Crystallogr Sect E Struct Rep Online. 2008 Aug 16;64:o1768. doi: 10.1107/S1600536808025592. PMID: 21201750; PMCID: PMC2960565.
Copy Download .nbib Format: NLM
The role of combinations of HIV protease inhibitors in the management of persons with HIV infection.

Expert opinion on investigational drugs

Moyle G.
PMID: 15991982
Expert Opin Investig Drugs. 1998 Mar;7(3):413-26. doi: 10.1517/13543784.7.3.413.

The current standard of care in antiretroviral therapy includes two nucleoside analogue reverse transcriptase inhibitors (NRTIs) plus a potent third agent, usually an HIV protease inhibitor (PI). However, around 20 - 30% of patients initiating therapy in clinical studies,...

Cite
Moyle G. The role of combinations of HIV protease inhibitors in the management of persons with HIV infection. Expert Opin Investig Drugs. 1998;7(3):413-26doi: 10.1517/13543784.7.3.413.
Moyle, G. (1998). The role of combinations of HIV protease inhibitors in the management of persons with HIV infection. Expert opinion on investigational drugs, 7(3), 413-26. https://doi.org/10.1517/13543784.7.3.413
Moyle, G. "The role of combinations of HIV protease inhibitors in the management of persons with HIV infection." Expert opinion on investigational drugs vol. 7,3 (1998): 413-26. doi: https://doi.org/10.1517/13543784.7.3.413
Moyle G. The role of combinations of HIV protease inhibitors in the management of persons with HIV infection. Expert Opin Investig Drugs. 1998 Mar;7(3):413-26. doi: 10.1517/13543784.7.3.413. PMID: 15991982.
Copy Download .nbib Format: NLM
Treatment of pediatric HIV infection.

Current infectious disease reports

d'Oulx EA, Chiappini E, de Martino M, Tovo PA.
PMID: 17880854
Curr Infect Dis Rep. 2007 Sep;9(5):425-33. doi: 10.1007/s11908-007-0065-5.

HIV-infected children require a peculiar management when compared to infected adults. Antiretroviral therapy has been quite well adapted to children, but new studies are needed to answer many unsolved questions, such as when to start therapy in asymptomatic infected...

Cite
d'Oulx EA, Chiappini E, de Martino M, et al. Treatment of pediatric HIV infection. Curr Infect Dis Rep. 2007;9(5):425-33doi: 10.1007/s11908-007-0065-5.
d'Oulx, E. A., Chiappini, E., de Martino, M., & Tovo, P. A. (2007). Treatment of pediatric HIV infection. Current infectious disease reports, 9(5), 425-33. https://doi.org/10.1007/s11908-007-0065-5
d'Oulx, Elisa A, et al. "Treatment of pediatric HIV infection." Current infectious disease reports vol. 9,5 (2007): 425-33. doi: https://doi.org/10.1007/s11908-007-0065-5
d'Oulx EA, Chiappini E, de Martino M, Tovo PA. Treatment of pediatric HIV infection. Curr Infect Dis Rep. 2007 Sep;9(5):425-33. doi: 10.1007/s11908-007-0065-5. PMID: 17880854.
Copy Download .nbib Format: NLM
Newer antiretroviral agents and how to use them.

Current infectious disease reports

Kim HH, Daar ES.
PMID: 19545503
Curr Infect Dis Rep. 2009 Jul;11(4):327-34. doi: 10.1007/s11908-009-0048-9.

Several relatively new antiretroviral drugs have been approved or are under investigation. These include nucleoside and nonnucleoside reverse transcriptase inhibitors, protease and integrase strand transfer inhibitors, CCR5 antagonists, and an entirely new class of maturation inhibitors. Although most of...

Cite
Kim HH, Daar ES. Newer antiretroviral agents and how to use them. Curr Infect Dis Rep. 2009;11(4):327-34doi: 10.1007/s11908-009-0048-9.
Kim, H. H., & Daar, E. S. (2009). Newer antiretroviral agents and how to use them. Current infectious disease reports, 11(4), 327-34. https://doi.org/10.1007/s11908-009-0048-9
Kim, Holly H, and Daar, Eric S. "Newer antiretroviral agents and how to use them." Current infectious disease reports vol. 11,4 (2009): 327-34. doi: https://doi.org/10.1007/s11908-009-0048-9
Kim HH, Daar ES. Newer antiretroviral agents and how to use them. Curr Infect Dis Rep. 2009 Jul;11(4):327-34. doi: 10.1007/s11908-009-0048-9. PMID: 19545503.
Copy Download .nbib Format: NLM
The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance.

Scientifica

Wainberg MA.
PMID: 24278679
Scientifica (Cairo). 2012;2012:238278. doi: 10.6064/2012/238278. Epub 2012 Dec 31.

The use of highly active antiretroviral therapy (HAART) involves combinations of drugs to achieve maximal virological response and reduce the potential for the emergence of antiviral resistance. There are two broad classes of reverse transcriptase inhibitors, the nucleoside reverse...

Cite
Wainberg MA. The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance. Scientifica (Cairo). 2012;2012:238278doi: 10.6064/2012/238278.
Wainberg, M. A. (2012). The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance. Scientifica, 2012238278. https://doi.org/10.6064/2012/238278
Wainberg, Mark A. "The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance." Scientifica vol. 2012 (2012): 238278. doi: https://doi.org/10.6064/2012/238278
Wainberg MA. The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance. Scientifica (Cairo). 2012;2012:238278. doi: 10.6064/2012/238278. Epub 2012 Dec 31. PMID: 24278679; PMCID: PMC3820659.
Copy Download .nbib Format: NLM
Tenofovir-associated renal dysfunction in clinical practice: An observational cohort from western India.

Indian journal of sexually transmitted diseases and AIDS

Patel KK, Patel AK, Ranjan RR, Patel AR, Patel JK.
PMID: 21808434
Indian J Sex Transm Dis AIDS. 2010 Jan;31(1):30-4. doi: 10.4103/0253-7184.68998.

BACKGROUND: Tenofovir (TDF) is preferred nucleoside reverse transcriptase inhibitors (NRTI) for the treatment of human immunodeficiency virus infection because of its potency and safety. Renal toxicity with TDF use is low and comparable with other NRTI in clinical trials,...

Cite
Patel KK, Patel AK, Ranjan RR, et al. Tenofovir-associated renal dysfunction in clinical practice: An observational cohort from western India. Indian J Sex Transm Dis AIDS. 2010;31(1):30-4doi: 10.4103/0253-7184.68998.
Patel, K. K., Patel, A. K., Ranjan, R. R., Patel, A. R., & Patel, J. K. (2010). Tenofovir-associated renal dysfunction in clinical practice: An observational cohort from western India. Indian journal of sexually transmitted diseases and AIDS, 31(1), 30-4. https://doi.org/10.4103/0253-7184.68998
Patel, Ketan K, et al. "Tenofovir-associated renal dysfunction in clinical practice: An observational cohort from western India." Indian journal of sexually transmitted diseases and AIDS vol. 31,1 (2010): 30-4. doi: https://doi.org/10.4103/0253-7184.68998
Patel KK, Patel AK, Ranjan RR, Patel AR, Patel JK. Tenofovir-associated renal dysfunction in clinical practice: An observational cohort from western India. Indian J Sex Transm Dis AIDS. 2010 Jan;31(1):30-4. doi: 10.4103/0253-7184.68998. PMID: 21808434; PMCID: PMC3140146.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 416 entries